Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 8, 212588
eCollection

Mitochondrial Disorders and Drugs: What Every Physician Should Know

Affiliations
Review

Mitochondrial Disorders and Drugs: What Every Physician Should Know

Daniele Orsucci et al. Drugs Context.

Abstract

Mitochondrial disorders are a group of metabolic conditions caused by impairment of the oxidative phosphorylation system. There is currently no clear evidence supporting any pharmacological interventions for most mitochondrial disorders, except for coenzyme Q10 deficiencies, Leber hereditary optic neuropathy, and mitochondrial neurogastrointestinal encephalomyopathy. Furthermore, some drugs may potentially have detrimental effects on mitochondrial dysfunction. Drugs known to be toxic for mitochondrial functions should be avoided whenever possible. Mitochondrial patients needing one of these treatments should be carefully monitored, clinically and by laboratory exams, including creatine kinase and lactate. In the era of molecular and 'personalized' medicine, many different physicians (not only neurologists) should be aware of the basic principles of mitochondrial medicine and its therapeutic implications. Multicenter collaboration is essential for the advancement of therapy for mitochondrial disorders. Whenever possible, randomized clinical trials are necessary to establish efficacy and safety of drugs. In this review we discuss in an accessible way the therapeutic approaches and perspectives in mitochondrial disorders. We will also provide an overview of the drugs that should be used with caution in these patients.

Keywords: coenzyme Q10; drugs; mitochondria; mitochondrial diseases; mtDNA; toxicity.

Conflict of interest statement

Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at http://www.drugsincontext.com/wp-content/uploads/2019/06/dic.212588-COI.pdf

Figures

Figure 1
Figure 1
Heteroplasmy and mitotic segregation: schematic representation. Because of the mitotic segregation (random share-out of mutated and nonmutated mitochondria between the daughter cells), the mutation load can change from one cell generation to the next, and with time, it can either surpass or fall below the pathogenic threshold.

Similar articles

See all similar articles

References

    1. DiMauro S, Schon EA, Carelli V, Hirano M. The clinical maze of mitochondrial neurology. Nat Rev Neurol. 2013;9(8):429–444. doi: 10.1038/nrneurol.2013.126. - DOI - PMC - PubMed
    1. Rahman J, Rahman S. Mitochondrial medicine in the omics era. Lancet. 2018;391(10139):2560–2574. doi: 10.1016/S0140-6736(18)30727-X. - DOI - PubMed
    1. Aryaman J, Johnston IG, Jones NS. Mitochondrial DNA density homeostasis accounts for a threshold effect in a cybrid model of a human mitochondrial disease. Biochem J. 2017;474(23):4019–4034. doi: 10.1042/BCJ20170651. - DOI - PMC - PubMed
    1. Luo S, Valencia CA, Zhang J, et al. Biparental inheritance of mitochondrial DNA in humans. Proc Natl Acad Sci U S A. 2018;115(51):13039–13044. doi: 10.1073/pnas.1810946115. - DOI - PMC - PubMed
    1. Kirkman MA, Yu-Wai-Man P, Korsten A, et al. Gene-environment interactions in Leber hereditary optic neuropathy. Brain. 2009;132(Pt 9):2317–2326. doi: 10.1093/brain/awp158. - DOI - PMC - PubMed
Feedback